Roivant Sciences

Contributing Author

Recent Articles by Roivant Sciences

Apr-02	Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) ROIV GlobeNewswire
Apr-02	Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) ROIV GlobeNewswire
Mar-28	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Mar-03	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna ROIV +6.00% ROIV GlobeNewswire
Mar-03	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Feb-06	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) ROIV +22.14% GlobeNewswire
Feb-06	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 ROIV +22.14% GlobeNewswire
Jan-23	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 ROIV GlobeNewswire
Dec-11	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day ROIV +5.43% GlobeNewswire
Nov-10	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update ROIV GlobeNewswire
Oct-27	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 ROIV GlobeNewswire
Sep-17	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) ROIV +7.76% GlobeNewswire
Sep-11	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List ROIV GlobeNewswire
Sep-03	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients ROIV GlobeNewswire
Aug-11	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update ROIV GlobeNewswire
Jul-28	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 ROIV GlobeNewswire
Jun-09	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis ROIV GlobeNewswire
May-29	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update ROIV +6.40% GlobeNewswire
May-15	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 ROIV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)